Remodelling of the heart after myocardial infarction

H D White1

  • 1Coronary Care Unit, Green Lane Hospital, Auckland, New Zealand.

Australian and New Zealand Journal of Medicine
|October 1, 1992
PubMed

Insights

Left ventricular remodeling after heart attack involves stretching and enlargement, increasing risks. Therapies like ACE inhibitors can reduce this dangerous dilatation, improving patient prognosis.

Area of Science:

  • Cardiovascular Science
  • Pathophysiology
  • Cardiac Remodeling

Background:

  • Coronary occlusion triggers infarct zone stretching via myocyte slippage.
  • Left ventricular remodeling and dilatation are progressive processes post-infarction.
  • Ventricular dilatation increases wall stress, oxygen demand, and arrhythmia risk.

Purpose of the Study:

  • To elucidate the mechanisms of left ventricular remodeling after myocardial infarction.
  • To identify determinants of infarct expansion and dilatation.
  • To review therapeutic strategies for mitigating adverse left ventricular remodeling.

Main Methods:

  • Review of pathophysiological processes following coronary occlusion.
  • Analysis of factors influencing infarct zone changes and ventricular dilatation.
  • Evaluation of existing and potential therapeutic interventions.

Main Results:

  • Infarct zone stretching and subsequent non-infarct zone hypertrophy characterize early remodeling.
  • Infarct size and infarct-related artery patency are key determinants of remodeling extent.
  • Late reperfusion and specific therapies can reverse or inhibit dilatation.

Conclusions:

  • Left ventricular dilatation is a detrimental, progressive process post-myocardial infarction.
  • End-systolic volume is a critical predictor of long-term prognosis.
  • Therapies such as ACE inhibition show promise in reducing left ventricular dilatation, though optimal strategies require further study.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...